WO2005009436A8 - Formulation dispersable d'un agent anti-inflammatoire - Google Patents

Formulation dispersable d'un agent anti-inflammatoire

Info

Publication number
WO2005009436A8
WO2005009436A8 PCT/IB2004/002461 IB2004002461W WO2005009436A8 WO 2005009436 A8 WO2005009436 A8 WO 2005009436A8 IB 2004002461 W IB2004002461 W IB 2004002461W WO 2005009436 A8 WO2005009436 A8 WO 2005009436A8
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory agent
dispersible formulation
dispersible
organ
formulation
Prior art date
Application number
PCT/IB2004/002461
Other languages
English (en)
Other versions
WO2005009436A1 (fr
Inventor
Nancy Jean Britten
Niki Ann Waldron
Jeffrey Lynn Watts
John Walter Hallberg
John William Ii Burns
Original Assignee
Pharmacia & Upjohn Co Llc
Nancy Jean Britten
Niki Ann Waldron
Jeffrey Lynn Watts
John Walter Hallberg
John William Ii Burns
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc, Nancy Jean Britten, Niki Ann Waldron, Jeffrey Lynn Watts, John Walter Hallberg, John William Ii Burns filed Critical Pharmacia & Upjohn Co Llc
Priority to AU2004258745A priority Critical patent/AU2004258745A1/en
Priority to BRPI0412581-9A priority patent/BRPI0412581A/pt
Priority to EP04744112A priority patent/EP1651210A1/fr
Priority to JP2006521702A priority patent/JP2007500691A/ja
Priority to MXPA06001288A priority patent/MXPA06001288A/es
Priority to CA002533101A priority patent/CA2533101A1/fr
Publication of WO2005009436A1 publication Critical patent/WO2005009436A1/fr
Publication of WO2005009436A8 publication Critical patent/WO2005009436A8/fr
Priority to IL172735A priority patent/IL172735A0/en
Priority to NO20060982A priority patent/NO20060982L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une méthode pour le traitement et/ou la prévention d'une pathologie inflammatoire dans un organe contenant un fluide et possédant un orifice extérieur naturel, par exemple la mamelle d'un animal produisant du lait, ou bien une oreille d'un sujet. L'invention concerne également une composition pharmaceutique dispersable injectable dans l'organe selon la méthode décrite, ainsi qu'un procédé pour préparer une telle composition.
PCT/IB2004/002461 2003-07-31 2004-07-19 Formulation dispersable d'un agent anti-inflammatoire WO2005009436A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2004258745A AU2004258745A1 (en) 2003-07-31 2004-07-19 Dispersible formulation of an anti-inflammatory agent
BRPI0412581-9A BRPI0412581A (pt) 2003-07-31 2004-07-19 formulação dispersável de um agente antiinflamatório
EP04744112A EP1651210A1 (fr) 2003-07-31 2004-07-19 Formulation dispersable d'un agent anti-inflammatoire
JP2006521702A JP2007500691A (ja) 2003-07-31 2004-07-19 抗炎症剤の分散性製剤
MXPA06001288A MXPA06001288A (es) 2003-07-31 2004-07-19 Formulacion dispersable de un agente anti-inflamatorio.
CA002533101A CA2533101A1 (fr) 2003-07-31 2004-07-19 Formulation dispersable d'un agent anti-inflammatoire
IL172735A IL172735A0 (en) 2003-07-31 2005-12-21 Dispersible formulation of an anti-inflammatory agent
NO20060982A NO20060982L (no) 2003-07-31 2006-02-28 Dispergerende formulering for et anti-inflammatorisk middel

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49212103P 2003-07-31 2003-07-31
US60/492,121 2003-07-31

Publications (2)

Publication Number Publication Date
WO2005009436A1 WO2005009436A1 (fr) 2005-02-03
WO2005009436A8 true WO2005009436A8 (fr) 2005-05-06

Family

ID=34103027

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/002461 WO2005009436A1 (fr) 2003-07-31 2004-07-19 Formulation dispersable d'un agent anti-inflammatoire

Country Status (14)

Country Link
EP (1) EP1651210A1 (fr)
JP (1) JP2007500691A (fr)
KR (1) KR100780983B1 (fr)
CN (1) CN1829510A (fr)
AU (1) AU2004258745A1 (fr)
BR (1) BRPI0412581A (fr)
CA (1) CA2533101A1 (fr)
CO (1) CO5650245A2 (fr)
IL (1) IL172735A0 (fr)
MX (1) MXPA06001288A (fr)
NO (1) NO20060982L (fr)
RU (1) RU2319508C2 (fr)
WO (1) WO2005009436A1 (fr)
ZA (1) ZA200600096B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081406A1 (es) * 2006-12-20 2008-10-17 Schering Plough Ltd Composiciones farmaceuticas de flunixina
GB0711776D0 (en) * 2007-06-18 2007-07-25 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
UA111147C2 (uk) * 2009-11-11 2016-04-11 Байєр Б.В. Способи та композиції для лікування або профілактики зовнішнього отиту
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
ES2391721T3 (es) * 2010-03-01 2012-11-29 Laboratorios Salvat, S.A. Disoluciones acuosas transparentes de acetónido de fluocinolona para el tratamiento de la infamación de oído
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
RU2486905C1 (ru) * 2012-05-28 2013-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ФГБОУ ВПО "КубГТУ") Средство для лечения мастита у животных
CN102784161A (zh) * 2012-08-01 2012-11-21 张吉川 一种治疗急慢性中耳炎的特效滴耳液
CA2897878A1 (fr) * 2013-01-14 2014-07-17 Infirst Healthcare Limited Compositions de solutions solides et utilisation dans le traitement d'une maladie cardiovasculaire
MX366317B (es) * 2013-02-04 2019-07-03 Infirst Healthcare Ltd Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
LV15071B (lv) * 2015-07-14 2016-02-20 Rīgas Stradiņa Universitāte Kompozīcija subklīniska mastīta ārstēšanai govīm
BR112018002227A2 (pt) 2015-08-05 2018-09-18 Childrens Medical Center composições com potencializadores de permeação para administração de fármaco
US10561684B2 (en) 2015-08-27 2020-02-18 Min Bo SHIM Pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus including platelet-rich plasma and method using the same
KR101738815B1 (ko) * 2015-08-27 2017-05-23 심민보 혈소판 풍부 혈장을 포함하는 감각신경성 난청 또는 이명을 예방 또는 치료하기 위한 약학적 조성물 및 이를 이용한 방법
WO2019191547A1 (fr) * 2018-03-29 2019-10-03 Yale University Nouveaux dérivés de pleuromutiline entièrement synthétiques et semi-synthétiques en tant que nouveaux antibiotiques et leur préparation
US20210308048A1 (en) * 2018-08-01 2021-10-07 Novilla Pharmaceuticals, Inc. Eutectic solvents comprising pharmaceutical agents, and methods of making and use thereof
RU2749857C1 (ru) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Способ борьбы со средним и наружным отитом
RU2751697C1 (ru) * 2020-09-09 2021-07-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Донской государственный аграрный университет" Средство для лечения отитов наружного слухового прохода у собак
KR102461699B1 (ko) * 2021-05-21 2022-11-03 현대약품 주식회사 벤지다민염산염을 포함하는 안정성이 개선된 가글액
KR20230084419A (ko) * 2021-12-03 2023-06-13 (주)인비보텍 난청 또는 이명의 예방 또는 치료용 조성물
KR20230084418A (ko) * 2021-12-03 2023-06-13 (주)인비보텍 난청 또는 이명의 예방 또는 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
EP0786986B1 (fr) * 1994-10-26 2002-03-20 Novartis AG Utilisation d'un alcool gras unsaturé
MX9701731A (es) * 1995-06-06 1997-10-31 Bayer Ag Composiciones anti-bacterianas oticas, no-irritantes, no-sensibles y no-toxicas para el oido.
DZ2479A1 (fr) * 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
CA2409123A1 (fr) * 2000-06-08 2001-12-13 The University Of Texas System Derives heterocycliques et techniques d'utilisation
PL363153A1 (en) * 2000-06-16 2004-11-15 Hercules Incorporated Chemically-modified antimicrobial peptides, compositions and methods of production and use
BR0112878A (pt) * 2000-09-12 2003-07-01 Upjohn Co Composição farmacêutica tendo atividade especìfica em água
US20040033938A1 (en) * 2000-09-12 2004-02-19 Britten Nancy J. Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions

Also Published As

Publication number Publication date
AU2004258745A1 (en) 2005-02-03
CO5650245A2 (es) 2006-06-30
MXPA06001288A (es) 2006-04-11
CA2533101A1 (fr) 2005-02-03
RU2319508C2 (ru) 2008-03-20
KR20060031873A (ko) 2006-04-13
WO2005009436A1 (fr) 2005-02-03
RU2006101628A (ru) 2006-08-27
NO20060982L (no) 2006-05-02
BRPI0412581A (pt) 2006-09-19
JP2007500691A (ja) 2007-01-18
CN1829510A (zh) 2006-09-06
KR100780983B1 (ko) 2007-11-30
ZA200600096B (en) 2007-02-28
IL172735A0 (en) 2006-04-10
EP1651210A1 (fr) 2006-05-03

Similar Documents

Publication Publication Date Title
WO2005009436A8 (fr) Formulation dispersable d'un agent anti-inflammatoire
WO2004082588A3 (fr) Formulation dispersible d'un agent anti-inflammatoire
WO2005023227A3 (fr) Formulations de nicotine et leurs utilisations
TWI265809B (en) Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
WO2006032500A3 (fr) Composition immunogene
WO2004060345A3 (fr) Compositions pharmaceutiques dispersibles
ES2082723B1 (es) Formulacion farmaceutica de fluoxetina en forma dispersable.
WO2005004803A3 (fr) Inhibiteurs de la beta-secretase de phenylcarboxylate destines au traitement de la maladie d'alzheimer
WO2005077093A3 (fr) Fabrication d'enzymes lysosomales hautement phosphorylees et utilisations associees
WO2004074232A8 (fr) Derives d'acide 1-phenylalcane-carboxylique pour le traitement de maladies neurodegeneratives
WO2006013441A3 (fr) Utilisation de bacteries probiotiques dans la preparation de compositions topiques destinees a la protection de la peau
WO2006010589A3 (fr) Mousse en gel post-moussant
WO2008125120A3 (fr) Extrait de trigonella foenum-graecum
WO2005065195A3 (fr) Inhibiteurs de phenylamide et de pyridylamide de la beta-secretase, traitant la maladie d'alzheimer
WO2005018545A3 (fr) Inhibiteurs macrocycliques de la beta-secretase destines au traitement de la maladie d'alzheimer
WO2005000232A3 (fr) Derives amino-amide a six elements tenant lieu d'inhibiteurs de l'angiogenese
WO2007067519A3 (fr) Utilisation de neurotransmetteurs et de neuropeptides pour le traitement de maladies de secheresse oculaire et de conditions associees
WO2007044348A3 (fr) Produits hygieniques anti-infectieux a base de phtalate d'acetate de cellulose
WO2004087181A8 (fr) Combinaisons de principes actifs d'huiles contenant des acides gras $g(v)3 avec des extraits vegetaux contenant des polyphenols et utilisation desdites combinaisons
WO2000040232A3 (fr) Nouvelles compositions et trousses de bretylium, et leur utilisation dans la prevention et le traitement des pathologies cardio-vasculaires
WO2005009472A3 (fr) Composition pharmaceutique dispersable pour le traitement de la mastite et des troubles otiques
WO2008042557A3 (fr) Composition et procédé pour un shampooing pour animaux
WO2003102206A3 (fr) Sgk et nedd utilises comme cibles diagnostiques et therapeutiques
WO2003024996A3 (fr) Macrocycles antibacteriens
WO2005051290A3 (fr) Methodes et preparations permettant de traiter des etats pathologiques associes a un taux eleve de dihydrotestosterone

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480022099.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 05/2005 UNDER (72,75) THE ADDRESS OF "BURNS, JOHN, WILLIAM, II" SHOULD READ "812 4TH AVENUE #8, ANTIGO, WI 54409 (US)."

WWE Wipo information: entry into national phase

Ref document number: 544310

Country of ref document: NZ

Ref document number: 172735

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 05130971

Country of ref document: CO

Ref document number: 6136/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006/00096

Country of ref document: ZA

Ref document number: 2004258745

Country of ref document: AU

Ref document number: 200600096

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2533101

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12006500226

Country of ref document: PH

Ref document number: 1020067002034

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/001288

Country of ref document: MX

Ref document number: 2006521702

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004258745

Country of ref document: AU

Date of ref document: 20040719

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004258745

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004744112

Country of ref document: EP

Ref document number: 2006101628

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004744112

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0412581

Country of ref document: BR